CL2021001537A1 - Formas cristalinas y formas de sal de un inhibidor de cinasa - Google Patents

Formas cristalinas y formas de sal de un inhibidor de cinasa

Info

Publication number
CL2021001537A1
CL2021001537A1 CL2021001537A CL2021001537A CL2021001537A1 CL 2021001537 A1 CL2021001537 A1 CL 2021001537A1 CL 2021001537 A CL2021001537 A CL 2021001537A CL 2021001537 A CL2021001537 A CL 2021001537A CL 2021001537 A1 CL2021001537 A1 CL 2021001537A1
Authority
CL
Chile
Prior art keywords
forms
relates
kinase inhibitor
compound
crystal
Prior art date
Application number
CL2021001537A
Other languages
English (en)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Peter Wong
Courtney S Johnson
Melanie Janelle Bevill
Stephan D Parent
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CL2021001537A1 publication Critical patent/CL2021001537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas cristalinas de la base libre del inhibidor de c-Met, Compuesto 1. La invención también se refiere a formas cristalinas de sales del Compuesto 1. La invención también se refiere a composiciones farmacéuticas que comprenden los polimorfos sólidos de la base libre y sales del Compuesto 1. La invención se refiere además a métodos para tratar una enfermedad, trastorno o síndrome mediado al menos en parte por la modulación de la actividad in vivo de una proteína cinasa.
CL2021001537A 2018-12-13 2021-06-11 Formas cristalinas y formas de sal de un inhibidor de cinasa CL2021001537A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
CL2021001537A1 true CL2021001537A1 (es) 2022-02-04

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001537A CL2021001537A1 (es) 2018-12-13 2021-06-11 Formas cristalinas y formas de sal de un inhibidor de cinasa

Country Status (20)

Country Link
US (1) US20230029213A1 (es)
EP (1) EP3894012A1 (es)
JP (2) JP2022512399A (es)
KR (1) KR20210102381A (es)
CN (1) CN113329790A (es)
AU (1) AU2019395419A1 (es)
BR (1) BR112021011333A2 (es)
CA (1) CA3122840A1 (es)
CL (1) CL2021001537A1 (es)
CO (1) CO2021007613A2 (es)
CR (1) CR20210375A (es)
GE (1) GEP20247596B (es)
IL (1) IL283860A (es)
MA (1) MA54458A (es)
MX (1) MX2021006951A (es)
PE (1) PE20211757A1 (es)
PH (1) PH12021551356A1 (es)
SG (1) SG11202105949RA (es)
TW (1) TW202039440A (es)
WO (1) WO2020123800A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820226A (zh) * 2018-01-26 2024-04-05 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
PE20230110A1 (es) * 2020-04-30 2023-01-25 Exelixis Inc Procesos para la preparacion de un inhibidor de cinasa
PE20231369A1 (es) 2020-07-31 2023-09-07 Exelixis Inc Combinaciones para el tratamiento del cancer
EP4240333A1 (en) 2020-11-05 2023-09-13 Exelixis, Inc. Pharmaceutical compositions of a kinase inhibitor
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371383T3 (es) * 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
RU2723050C2 (ru) 2013-05-02 2020-06-08 Анаптисбайо, Инк. Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
CN117820226A (zh) * 2018-01-26 2024-04-05 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
PE20220962A1 (es) * 2019-06-03 2022-06-10 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas

Also Published As

Publication number Publication date
EP3894012A1 (en) 2021-10-20
JP2022512399A (ja) 2022-02-03
IL283860A (en) 2021-07-29
CN113329790A (zh) 2021-08-31
MX2021006951A (es) 2021-07-15
US20230029213A1 (en) 2023-01-26
WO2020123800A1 (en) 2020-06-18
MA54458A (fr) 2021-10-20
GEP20247596B (en) 2024-02-26
JP2024038167A (ja) 2024-03-19
TW202039440A (zh) 2020-11-01
CA3122840A1 (en) 2020-06-18
PE20211757A1 (es) 2021-09-07
KR20210102381A (ko) 2021-08-19
CR20210375A (es) 2021-08-18
SG11202105949RA (en) 2021-07-29
PH12021551356A1 (en) 2021-12-06
CO2021007613A2 (es) 2021-06-21
BR112021011333A2 (pt) 2021-08-31
AU2019395419A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CL2021003205A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CY1125083T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CL2020003101A1 (es) Sales de sepiapterina farmacéuticamente aceptables.
ECSP109979A (es) Preparación sólida que contiene alogliptina y clorhidrato de metformina
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
CL2017001574A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
CL2023001268A1 (es) Composiciones farmacéuticas de un inhibidor de cinasa
CL2022001183A1 (es) Formas de sal de un receptor del componente c5a del complemento
CO2020008769A2 (es) Moduladores de la expresión dnm2
CO2020003134A2 (es) Moduladores de la expresión de enac
MX2020004250A (es) Composicion farmaceutica de liberacion sostenida.
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
UY38133A (es) Nuevos inhibidores de cdk8/19